MX2020005640A - Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. - Google Patents
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.Info
- Publication number
- MX2020005640A MX2020005640A MX2020005640A MX2020005640A MX2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A MX 2020005640 A MX2020005640 A MX 2020005640A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- breast cancer
- antibodies
- humanized anti
- liv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593660P | 2017-12-01 | 2017-12-01 | |
| PCT/US2018/063425 WO2019109007A1 (en) | 2017-12-01 | 2018-11-30 | Humanized anti-liv1 antibodies for the treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005640A true MX2020005640A (es) | 2020-08-20 |
Family
ID=64746653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005640A MX2020005640A (es) | 2017-12-01 | 2018-11-30 | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200283540A1 (https=) |
| EP (1) | EP3717518A1 (https=) |
| JP (2) | JP2021505540A (https=) |
| KR (1) | KR20200090838A (https=) |
| CN (1) | CN111757892A (https=) |
| AU (1) | AU2018375182A1 (https=) |
| BR (1) | BR112020010937A2 (https=) |
| CA (1) | CA3084495A1 (https=) |
| EA (1) | EA202091360A1 (https=) |
| IL (1) | IL274766A (https=) |
| MA (1) | MA50943A (https=) |
| MX (1) | MX2020005640A (https=) |
| SG (1) | SG11202004751TA (https=) |
| WO (1) | WO2019109007A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2648752B1 (en) | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| MX2018010847A (es) | 2016-03-15 | 2019-07-04 | Seattle Genetics Inc | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| AU2020318975A1 (en) * | 2019-07-22 | 2022-03-17 | Seagen Inc. | Humanized anti-LIV1 antibodies for the treatment of cancer |
| KR20220114002A (ko) * | 2019-12-09 | 2022-08-17 | 씨젠 인크. | Liv1-adc 및 pd-1 길항제를 사용하는 병용 요법 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| CN119317646A (zh) * | 2022-06-16 | 2025-01-14 | 山东博安生物技术股份有限公司 | 抗liv-1抗体及其药物偶联物 |
| IL322565A (en) | 2023-02-07 | 2025-10-01 | Lanova Medicines Ltd | Antibodies targeting liv-1 and their uses |
| AU2024235054A1 (en) * | 2023-03-15 | 2025-10-02 | BioRay Pharmaceutical Co., Ltd. | Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof |
| WO2025146137A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1抗体药物偶联物及其用途 |
| CN120040587B (zh) * | 2025-04-27 | 2025-08-08 | 上海宏成药业有限公司 | 抗liv-1抗体或其抗原结合片段及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| TW200813231A (en) * | 2006-04-13 | 2008-03-16 | Novartis Vaccines & Diagnostic | Methods of treating, diagnosing or detecting cancer |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EP2648752B1 (en) * | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| MX2014013763A (es) * | 2012-05-11 | 2015-02-20 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. |
| US9492566B2 (en) * | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2015175533A2 (en) * | 2014-05-13 | 2015-11-19 | Immunogen, Inc. | Anti-cd37 immunoconjugate dosing regimens |
| MX2018010847A (es) * | 2016-03-15 | 2019-07-04 | Seattle Genetics Inc | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. |
-
2018
- 2018-11-30 SG SG11202004751TA patent/SG11202004751TA/en unknown
- 2018-11-30 KR KR1020207017651A patent/KR20200090838A/ko not_active Abandoned
- 2018-11-30 MA MA050943A patent/MA50943A/fr unknown
- 2018-11-30 BR BR112020010937-1A patent/BR112020010937A2/pt not_active IP Right Cessation
- 2018-11-30 CN CN201880077514.3A patent/CN111757892A/zh active Pending
- 2018-11-30 EA EA202091360A patent/EA202091360A1/ru unknown
- 2018-11-30 EP EP18822563.5A patent/EP3717518A1/en not_active Withdrawn
- 2018-11-30 WO PCT/US2018/063425 patent/WO2019109007A1/en not_active Ceased
- 2018-11-30 AU AU2018375182A patent/AU2018375182A1/en not_active Abandoned
- 2018-11-30 CA CA3084495A patent/CA3084495A1/en active Pending
- 2018-11-30 MX MX2020005640A patent/MX2020005640A/es unknown
- 2018-11-30 JP JP2020529281A patent/JP2021505540A/ja active Pending
- 2018-11-30 US US16/768,020 patent/US20200283540A1/en not_active Abandoned
-
2020
- 2020-05-19 IL IL274766A patent/IL274766A/en unknown
-
2023
- 2023-03-07 US US18/179,560 patent/US20240076402A1/en not_active Abandoned
- 2023-10-06 JP JP2023173950A patent/JP2024001187A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MA50943A (fr) | 2020-10-07 |
| IL274766A (en) | 2020-07-30 |
| CA3084495A1 (en) | 2019-06-06 |
| AU2018375182A1 (en) | 2020-06-11 |
| WO2019109007A1 (en) | 2019-06-06 |
| EP3717518A1 (en) | 2020-10-07 |
| SG11202004751TA (en) | 2020-06-29 |
| JP2024001187A (ja) | 2024-01-09 |
| JP2021505540A (ja) | 2021-02-18 |
| US20200283540A1 (en) | 2020-09-10 |
| CN111757892A (zh) | 2020-10-09 |
| KR20200090838A (ko) | 2020-07-29 |
| US20240076402A1 (en) | 2024-03-07 |
| BR112020010937A2 (pt) | 2020-11-17 |
| EA202091360A1 (ru) | 2020-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005640A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. | |
| ZA201707869B (en) | Anti-ntb-a antibodies and related compositions and methods | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2020005463A (es) | Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer. | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
| NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| EA201990293A1 (ru) | Мультиспецифичные антитела против cd40 и cd137 | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| MX2021013118A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
| EP4268843A3 (en) | Improved il-6 antibodies | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| MX2018005348A (es) | Composiciones y metodos para transduccion de tumores. | |
| EA201890442A1 (ru) | Получение фоторецепторов для лечения заболеваний сетчатки | |
| EP4275746A3 (en) | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| WO2017035319A8 (en) | Methods for treatment of polycystic kidney disease | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| JOP20200090A1 (ar) | عملية لتحضير بنزوثيوفين-2 يل بورونات | |
| AU2018288712A1 (en) | Methods for treating merkel cell carcinoma (MCC) using NK-92 cells |